01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
23:14 , Apr 11, 2019 |  BC Innovations  |  Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
12:44 , Mar 21, 2019 |  BC Innovations  |  Emerging Company Profile

A Passage to optimal CNS vectors

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched...
23:30 , Feb 13, 2019 |  BC Week In Review  |  Financial News

Harpoon slips after pricing $75.6M IPO

Harpoon Therapeutics Inc. (NASDAQ:HARP) raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon sold 5.4 million shares at $14, within the $13-$15 range. The price gave Harpoon a...
04:00 , Feb 8, 2019 |  BC Extra  |  Financial News

Harpoon slips after pricing $75.6M IPO

Harpoon Therapeutics Inc. (NASDAQ:HARP) shares lost $0.50 to $13.50 in their first day of trading Friday after the company raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon...
01:56 , Feb 8, 2019 |  BC Week In Review  |  Financial News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's disease. The immuno-neurology company sold 9.3 million shares at...
23:41 , Feb 7, 2019 |  BC Innovations  |  Finance

Pharma ventures earlier

Facing the squeeze from inside and out, at least three corporate venture arms are revamping operations to increase their foothold in earlier and riskier investment opportunities. From one side, the move reflects the growing reliance...
03:46 , Feb 7, 2019 |  BC Extra  |  Company News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) shares fell $1 to $18 Thursday after the company raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's...
20:45 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Alector amends IPO

Immuno-neurology company Alector Inc. (South San Francisco, Calif.) amended its IPO on NASDAQ and now plans to sell 9.3 million shares at $18-$20. At the midpoint, the company would raise $175.8 million and be valued...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...